Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Immunol ; 208(3): 594-602, 2022 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-35022272

RESUMO

The coinhibitory receptor lymphocyte activation gene 3 (LAG-3) is an immune checkpoint molecule that negatively regulates T cell activation, proliferation, and homeostasis. Blockade or deletion of LAG-3 in autoimmune-prone backgrounds or induced-disease models has been shown to exacerbate disease. We observed significantly fewer LAG-3+ CD4 and CD8 T cells from subjects with relapsing-remitting multiple sclerosis (RRMS) and type 1 diabetes. Low LAG-3 protein expression was linked to alterations in mRNA expression and not cell surface cleavage. Functional studies inhibiting LAG-3 suggest that in subjects with RRMS, LAG-3 retains its ability to suppress T cell proliferation. However, LAG-3 expression was associated with the expression of markers of apoptosis, indicating a role for low LAG-3 in T cell resistance to cell death. In T cells from subjects with RRMS, we observed a global dysregulation of LAG-3 expression stemming from decreased transcription and persisting after T cell stimulation. These findings further support the potential clinical benefits of a LAG-3 agonist in the treatment of human autoimmunity.


Assuntos
Antígenos CD/metabolismo , Linfócitos T CD4-Positivos/metabolismo , Linfócitos T CD8-Positivos/metabolismo , Diabetes Mellitus Tipo 1/imunologia , Esclerose Múltipla Recidivante-Remitente/imunologia , Apoptose/fisiologia , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD8-Positivos/imunologia , Proliferação de Células/fisiologia , Regulação da Expressão Gênica/genética , Humanos , Ativação Linfocitária/imunologia , RNA Mensageiro/biossíntese , Proteína do Gene 3 de Ativação de Linfócitos
2.
Neurol Clin Pract ; 5(1): 67-73, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25717421

RESUMO

Electronic medical records (EMRs) are being rapidly adapted in the United States with goals of improving patient care, increasing efficiency, and reducing costs. Neurologists must become knowledgeable about the utility and effectiveness of the important parts of these systems specifically needed for care of neurology patients. The field of neurology encompasses complex disorders whose diagnosis and management heavily relies on detailed medical documentation of history and physical examination, and often on specialty-specific ancillary tests and extensive neuroimaging. Small discrepancies in documentation or absence of an in-hand ancillary test result can drastically change the current workup or treatment decision of a complex patient with neurologic disease. We describe current models and opportunities for improvements to EMRs that provide utility and efficiency in the care of neurology patients.

3.
Cephalalgia ; 35(9): 807-15, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25366551

RESUMO

OBJECTIVE: The objective of this article is to compare acute primary headache patient outcomes in those initially treated with parenteral opiates or non-opiate recommended headache medications in a large academic medical emergency department (ED). BACKGROUND: Many acute primary headache patients are not diagnosed with a specific headache type and are treated with opiates and nonspecific pain medications in the ED setting. This is inconsistent with multiple expert recommendations. METHODS: Electronic charts were reviewed from 574 consecutive patients who visited the ED for acute primary headache (identified by chief complaint and ICD9 codes) and were treated with parenteral medications. RESULTS: Non-opiate recommended headache medications were given first line to 52.6% and opiates to 22.8% of all participants. Patients given opiates first had significantly longer length of stays (median 5.0 vs. 3.9 hours, p < 0.001) and higher rates of return ED visits within seven days (7.6% vs. 3.0%, p = 0.033) compared with those given non-opiate recommended medications in univariate analysis. Only the association with longer length of stay remained significant in multivariable regression including possible confounding variables. CONCLUSIONS: Initial opiate use is associated with longer length of stay compared with non-opiate first-line recommended medications for acute primary headache in the ED. This association remained strong and significant even after multivariable adjustment for headache diagnosis and other possible confounders.


Assuntos
Analgésicos Opioides/uso terapêutico , Serviço Hospitalar de Emergência/estatística & dados numéricos , Transtornos da Cefaleia Primários/tratamento farmacológico , Padrões de Prática Médica/estatística & dados numéricos , Centros Médicos Acadêmicos , Doença Aguda , Analgésicos/uso terapêutico , Transtornos da Cefaleia Primários/diagnóstico , Humanos , Tempo de Internação
4.
J Am Geriatr Soc ; 57(1): 115-9, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19054178

RESUMO

OBJECTIVES: To determine the prevalence of chronic pain in elderly people and its relationship with obesity and associated comorbidities and risk factors. DESIGN: Cross-sectional. SETTING: Community. PARTICIPANTS: A representative community sample of 840 subjects aged 70 and older. MEASUREMENTS: The prevalence of chronic pain and its relationship with obesity (categories defined according to body mass index (BMI)), other medical risk factors, and psychiatric comorbidities were examined. Chronic pain was defined as pain of at least moderate severity (> or =4 on a 10-point scale) some, most, or all of the time for the previous 3 months. RESULTS: The sample was mostly female (62.8%), and the average age was 80 (range 70-101). The prevalence of chronic pain was 52% (39.7% in men; 58.9% in women). Subjects with chronic pain were more likely to report a diagnosis of depression (odds ratio (OR)=2.5, 95% confidence interval (CI)=1.40-4.55) and anxiety (OR=2.3, 95% CI=1.22-4.64). Obese subjects (BMI 30-34.9) were twice as likely (OR=2.1, 95%CI=1.33-3.28) and severely obese subjects (BMI> or =35) were more than four times as likely (OR=4.5, 95% CI=1.85-12.63) as those of normal weight (BMI 18.5-24.9) to have chronic pain. Obese subjects were significantly more likely to have chronic pain in the head, neck or shoulder, back, legs or feet, and abdomen or pelvis than subjects who were not obese. In multivariate models, obesity (OR=2.0, 95% CI=1.27-3.26) and severe obesity (OR=4.1, 95% CI=1.57-10.82) were associated with chronic pain after adjusting for age, sex, diabetes mellitus, hypertension, depression, anxiety, and education. CONCLUSION: Chronic pain is common in this elderly population, affects women more than men, and is highly associated with obesity.


Assuntos
Obesidade/epidemiologia , Dor/epidemiologia , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Doença Crônica , Comorbidade , Estudos Transversais , Feminino , Humanos , Masculino , Prevalência , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA